SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ariella who wrote (1152)8/20/1998 9:19:00 AM
From: yosi s  Read Replies (1) of 1491
 
" free samples"

just as a minor correction.
Most time free sample do not factor in Rx written. Rx written is sampled by monitoring pharmacies. and the number is not important at this stage as the trend, rate of growth, do the same physicians write more, do more physician write up. In order to make sense this number as to reach a certain critical mass, It is only a matter of time. So if Revenues grew in the next 6-9 months to get above burn rate we got a winner.
If partner comes for Alrex and pays up front, then they have more time. Once HU211 release is out, expect a partner to join in.
Payment to PARS will be given as well.
With European introduction for Alrex and Lotemax, revenues should increase.

As for the price being down....( carry-over from prior phase.)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News